By admin | Published:
March 21, 2008
Giorgio Scagliotti
Robert Pirker
GIORGIO SCAGLIOTTI, University of Turin
ROBERT PIRKER, Medical University of Vienna
A heated debate took place at the European Congress on Lung Cancer in Turin between Robert Pirker who is in favor of offering adjuvant chemotherapy to selected patients who have stage I non-small cell lung cancer, and Giorgio Scagliotti who took the opposite point of view. Peter Goodwin got them together and asked them to talk about the key issues influencing their views.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
March 17, 2008
Nick Thatcher
NICK THATCHER, Christie Hospital, Manchester
There is a proven benefit in survival if you give your patients cis-platinum based chemotherapy after resection for non-small cell lung cancer. Nick Thatcher emphasized this fact at the beginning of his talk in Turin about front line therapy for non-small cell lung cancer. He went on to discuss optimizing therapy with respect to histology, performance status and the addition of targeted agents. Peter Goodwin interviewed him about his recommendations.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
March 17, 2008
Egbert Smit
EGBERT SMIT, Free University of Amsterdam
There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He talked with Peter Goodwin about insulin-like growth factor inhibitors, heat shock protein and an inhibitor of angiogenesis involving the c-MET protein.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
March 17, 2008
Silvia Novello
SILVIA NOVELLO, University of Turin
Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello when she presented data on a range of drugs which target angiogenesis by inhibiting more than one tyrosine kinase pathway. She talked about the evidence so far with Peter Goodwin.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
March 16, 2008
Christian Manegold
Nick Thatcher
Christian Manegold, Heidelberg University Medical Center, Manheim
Nick Thatcher, Christie Hospital, Manchester
Is bevacizumab a new standard of care for patients with unresectable non-small cell lung cancer who have good performance status? This question was raised in a debate at the European Congress on Lung Cancer held in Turin. Christian Manegold provided delegates with evidence from the AVAil and ECOG 4599 studies which underpin current approval of this anti-vascular endothelial growth factor (VEG-F) antibody. Nick Thatcher pointed out the limitations. They both talked with Peter Goodwin.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
March 16, 2008
Robert Pirker
ROBERT PIRKER , Medical University of Vienna
Phase III study results have detected improvements in overall survival among patients with advanced non-small cell lung cancer treated with a monoclonal antibody targeted to the epidermal growth factor receptor: EGFR. Robert Pirker told the Turin congress he thinks is an emerging role for EGRF-targeted antibodies in lung cancer for patients who test positive for the epidermal growth factor receptor. He discussed the data with Peter Goodwin.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Posted in News | Tagged cancer, cetuximab, improvements, lung, medication, monoclonal, patient, receptor, study, survival, test |
By admin | Published:
March 16, 2008
Ugo Pastorino
UGO PASTORINO , Istituto Nazionale Tumori, Milan
Even the most sophisticated and powerful detection method for lung cancer detection, spiral CT, is still unproven in the context of mass screening for lung cancer. At the conference in Turin, Ugo Pastorino, urged delegates to wait for the findings of the large randomized studies of spiral CT now being conducted before deciding whether to use this technique. He discussed his group’s findings with Peter Goodwin.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
March 16, 2008
Volume 16 Number 6 (March 15th, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)
Chemotherapy Foundation Symposium, November 7-10, 2007, New York
David Maloney
Nonmyeloablative Alogeneic Transplants Ready for Prime-Time in Follicular Lymphoma?
David Maloney, Fred Hutchinson Cancer Research Center, Seattle
Allogeneic transplantation is now a good option for treating some patient groups with follicular lymphoma. David Maloney explained to Peter Goodwin in Paris how his group has harnessed graft-versus-tumor effect by using nonmyeloablative conditioning without causing unacceptable risks of graft-versus-host disease.
Read More »
Posted in Oncology | Tagged agent, ash, cancer, chemo, disease, drug, hematologic, imatinib, leukemia, london, rituximab, transplant, treatment |
By admin | Published:
March 4, 2008
Volume 16 Number 5 (March 1st, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
Gastrointestinal Cancers Symposium (January 25-27, 2008, Orlando)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)
Richard Stone
George Canellos
Dasatinib: Durable Responses in Chronic Myeloid Leukemia
Richard Stone, Dana-Farber Cancer Institute, Boston
COMMENT: George Canellos, Dana-Farber Cancer Institute, Boston
Data released at the ASH conference show that dasatinib has given durable responses in patients with chronic phase chronic myeloid leukemia for whom imatinib has failed, or who cannot tolerate imatinib. In Atlanta Richard Stone discussed his findings with Derek Thorne, who then asked George Canellos to reflect on them.
Read More »
Posted in Oncology | Tagged chemo, conference, gastrointestinal, hematologic, myelodysplastic, myeloid, myeloma, pancreas, radiation, symposium, transplant, treatment |
